Invasive Fusariosis in Patients with Hematologic Diseases

Overview

Journal J Fungi (Basel)

Date 2021 Oct 23

PMID 34682236

Citations 10

Authors

Marcio Nucci

Gloria Barreiros

Tiyomi Akiti

Elias Anaissie

Simone A Nouer

Affiliations

Soon will be listed here.

Abstract

species are filamentous fungi widely encountered in nature, and may cause invasive disease in patients with hematologic conditions. Patients at higher risk are those with acute leukemia receiving induction remission chemotherapy or allogeneic hematopoietic cell transplant recipients. In these hosts, invasive fusariosis presents typically with disseminated disease, fever, metastatic skin lesions, pneumonia, and positive blood cultures. The prognosis is poor and the outcome is largely dependent on the immune status of the host, with virtually a 100% death rate in persistently neutropenic patients, despite monotherapy or combination antifungal therapy. In this paper, we will review the epidemiology, clinical manifestations, diagnosis, and management of invasive fusariosis affecting patients with hematologic diseases.

Citing Articles

Landscape of Invasive Fusariosis in Pediatric Cancer Patients: Results of a Multicenter Observational Study From Latin America.

Carlesse F, da Silva A, Sztajnbok J, Litivinov N, Peron K, Otsuka M Open Forum Infect Dis. 2024; 11(6):ofae285.

PMID: 38872851 PMC: 11170500. DOI: 10.1093/ofid/ofae285.

Clinical spectrum of fusariosis from a tertiary care center in India- a retrospective study.

Sudhaharan S, Pamidimukkala U, Singh K, Chavali P Iran J Microbiol. 2024; 16(1):145-150.

PMID: 38682054 PMC: 11055442. DOI: 10.18502/ijm.v16i1.14884.

Multicenter Retrospective Study of Invasive Fusariosis in Intensive Care Units, France.

Demonchy J, Biard L, Clere-Jehl R, Wallet F, Mokart D, Moreau A Emerg Infect Dis. 2024; 30(2).

PMID: 38270146 PMC: 10826781. DOI: 10.3201/eid3002.231221.

First report of fatal fungemia due in a patient with COVID-19 in Ecuador.

Jimbo-Zapata A, Sevillano G, Rodriguez P, Ramirez-Iglesias J, Navarro J Med Mycol Case Rep. 2024; 43:100622.

PMID: 38225951 PMC: 10788292. DOI: 10.1016/j.mmcr.2023.100622.

Fusariosis in patients with hematological malignancies: Two case reports.

Raymakers J, Castelijn D, Rutten C, Hodiamont C Med Mycol Case Rep. 2023; 42:100602.

PMID: 37767184 PMC: 10520354. DOI: 10.1016/j.mmcr.2023.08.005.

References

Guarana M, Nouer S, Nucci M . EQUAL Fusariosis score 2021: An European Confederation of Medical Mycology score derived from current guidelines to measure QUALity of the clinical management of invasive fusariosis. Mycoses. 2021; 64(12):1542-1545. DOI: 10.1111/myc.13321. View

Cordonnier C, Rovira M, Maertens J, Olavarria E, Faucher C, Bilger K . Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica. 2010; 95(10):1762-8. PMC: 2948103. DOI: 10.3324/haematol.2009.020073. View

Nucci M, Shoham S, Abdala E, Hamerschlak N, Rico J, Forghieri F . Outcomes of patients with invasive fusariosis who undergo further immunosuppressive treatments, is there a role for secondary prophylaxis?. Mycoses. 2019; 62(5):413-417. DOI: 10.1111/myc.12901. View

Nucci M, Marr K, Vehreschild M, De Souza C, Velasco E, Cappellano P . Improvement in the outcome of invasive fusariosis in the last decade. Clin Microbiol Infect. 2013; 20(6):580-5. DOI: 10.1111/1469-0691.12409. View

Ranawaka R, Nagahawatte A, Gunasekara T . Fusarium onychomycosis: prevalence, clinical presentations, response to itraconazole and terbinafine pulse therapy, and 1-year follow-up in nine cases. Int J Dermatol. 2015; 54(11):1275-82. DOI: 10.1111/ijd.12906. View

Kontoyiannis D, Marr K, Park B, Alexander B, Anaissie E, Walsh T . Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010; 50(8):1091-100. DOI: 10.1086/651263. View

Campo M, Lewis R, Kontoyiannis D . Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998-2009. J Infect. 2010; 60(5):331-7. DOI: 10.1016/j.jinf.2010.01.010. View

Nucci M, Jenks J, Thompson G, Hoenigl M, Dos Santos M, Forghieri F . Do high MICs predict the outcome in invasive fusariosis?. J Antimicrob Chemother. 2020; 76(4):1063-1069. DOI: 10.1093/jac/dkaa516. View

Hoenigl M, Salmanton-Garcia J, Walsh T, Nucci M, Neoh C, Jenks J . Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for.... Lancet Infect Dis. 2021; 21(8):e246-e257. DOI: 10.1016/S1473-3099(20)30784-2. View

10.

Badali H, Canete-Gibas C, Patterson H, Sanders C, Mermella B, Garcia V . In vitro activity of olorofim against clinical isolates of the Fusarium oxysporum and Fusarium solani species complexes. Mycoses. 2021; 64(7):748-752. DOI: 10.1111/myc.13273. View

11.

Walsh T, McCarthy M . The expanding use of matrix-assisted laser desorption/ionization-time of flight mass spectroscopy in the diagnosis of patients with mycotic diseases. Expert Rev Mol Diagn. 2019; 19(3):241-248. DOI: 10.1080/14737159.2019.1574572. View

12.

Kadri S, Remy K, Strich J, Gea-Banacloche J, Leitman S . Role of granulocyte transfusions in invasive fusariosis: systematic review and single-center experience. Transfusion. 2015; 55(9):2076-85. PMC: 4573241. DOI: 10.1111/trf.13099. View

13.

Fernandez-Cruz A, Semiglia M, Guinea J, Martinez-Jimenez M, Escribano P, Kwon M . A retrospective cohort of invasive fusariosis in the era of antimould prophylaxis. Med Mycol. 2019; 58(3):300-309. DOI: 10.1093/mmy/myz060. View

14.

Nucci F, Nouer S, Capone D, Anaissie E, Nucci M . Fusariosis. Semin Respir Crit Care Med. 2015; 36(5):706-14. DOI: 10.1055/s-0035-1562897. View

15.

Marom E, Holmes A, Bruzzi J, Truong M, OSullivan P, Kontoyiannis D . Imaging of pulmonary fusariosis in patients with hematologic malignancies. AJR Am J Roentgenol. 2008; 190(6):1605-9. DOI: 10.2214/AJR.07.3278. View

16.

Cornely O, Maertens J, Winston D, Perfect J, Ullmann A, Walsh T . Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007; 356(4):348-59. DOI: 10.1056/NEJMoa061094. View

17.

Scheel C, Hurst S, Barreiros G, Akiti T, Nucci M, Arunmozhi Balajee S . Molecular analyses of Fusarium isolates recovered from a cluster of invasive mold infections in a Brazilian hospital. BMC Infect Dis. 2013; 13:49. PMC: 3579725. DOI: 10.1186/1471-2334-13-49. View

18.

Cummings J, Jamison G, Boudreaux J, Howles M, Walsh T, Hayden R . Cross-reactivity of non-Aspergillus fungal species in the Aspergillus galactomannan enzyme immunoassay. Diagn Microbiol Infect Dis. 2007; 59(1):113-5. DOI: 10.1016/j.diagmicrobio.2007.04.022. View

19.

Nucci M, Anaissie E . Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin Infect Dis. 2002; 35(8):909-20. DOI: 10.1086/342328. View

20.

Lerolle N, Raffoux E, Socie G, Touratier S, Sauvageon H, Porcher R . Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study. Clin Microbiol Infect. 2014; 20(11):O952-9. DOI: 10.1111/1469-0691.12688. View